The HEXIM2 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of hexamethylene bisacetamide inducible protein 2 (HEXIM2). This product provides a heterogeneous pool of NCI-H1975 cells carrying targeted disruptions in the HEXIM2 gene, enabling researchers to investigate the consequences of abrogated HEXIM2 expression on transcriptional regulation and cellular phenotypes. The polyclonal format preserves genetic diversity and allows the study of gene-disrupted pools rather than single-clone artifacts, making it suitable for initial screening and population-level analyses.
The host NCI-H1975 cell line is a well-characterized human lung adenocarcinoma epithelial model harboring EGFR mutations (L858R and T790M), which are common in non-small cell lung cancer (NSCLC). These mutations render the cells dependent on oncogenic EGFR signaling and confer resistance to first-generation EGFR tyrosine kinase inhibitors. NCI-H1975 cells are widely used to study EGFR-mutant NSCLC biology, drug resistance mechanisms, and therapeutic response, providing a clinically relevant background for dissecting transcriptional dysregulation in lung cancer.
HEXIM2 functions as a critical negative regulator of the positive transcription elongation factor b (P-TEFb), a heterodimer of CDK9 and Cyclin T1. It assembles into the 7SK small nuclear ribonucleoprotein (snRNP) complex with 7SK snRNA, LARP7, and MePCE, sequestering P-TEFb in an inactive state and preventing CDK9-mediated phosphorylation of RNA polymerase II to repress transcriptional elongation. HEXIM2 activity is modulated by upstream signals including PI3K/AKT signaling and Brd4, which controls the release of active P-TEFb. Downstream, loss of HEXIM2 de-represses transcription of MYC, FOS, and CCND1, and enhances CDK9 kinase activity. By regulating the equilibrium between active and inactive P-TEFb, HEXIM2 governs transcriptional elongation and cell cycle progression.
Within the EGFR-mutant NCI-H1975 background, disruption of HEXIM2 is expected to release P-TEFb from inhibitory constraint, potentially amplifying transcriptional programs driven by oncogenic signals. This hyperactivation of RNA polymerase II-dependent elongation may exacerbate the malignant phenotype, increasing expression of cell cycle regulators and survival factors. Consequently, this knockout model serves as a powerful tool to examine how dysregulated transcriptional elongation collaborates with EGFR signaling to promote lung adenocarcinoma progression, drug resistance, and tumor heterogeneity. The model also provides a platform for investigating the broader role of HEXIM2 in transcriptional checkpoint control and its potential as a therapeutic vulnerability.
Researchers can employ HEXIM2 knockout NCI-H1975 polyclonal cells in a variety of experiments, including transcriptional elongation studies using RNA-seq or ChIP-qPCR to map RNA polymerase II occupancy and nascent transcription. The model is suited for P-TEFb inhibitor development and functional dissection of the 7SK snRNP complex. It can be integrated with drug sensitivity assays to evaluate how HEXIM2 loss modulates response to EGFR tyrosine kinase inhibitors or other anticancer agents, and apoptosis assays to assess cell survival dependencies. Additional applications encompass investigation of HEXIM2??s role in cell cycle regulation and its interplay with Brd4-mediated transcriptional activation. For technical inquiries or further details on assay compatibility, please contact Ascent Research.
